Live Earnings Conference Call: Biofrontera will host a live Q1 2026 earnings call on May 14, 2026 at 11:00AM ET. NASDAQ:BFRI Biofrontera Q1 2026 Earnings Report $0.96 -0.05 (-4.97%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$0.96 0.00 (-0.50%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallBiofrontera Q1 202600:00 / 00:00Live Transcript Follow Audio Biofrontera EPS ResultsActual EPSN/AConsensus EPS -$0.12Beat/MissN/AOne Year Ago EPSN/ABiofrontera Revenue ResultsActual RevenueN/AExpected Revenue$10.25 millionBeat/MissN/AYoY Revenue GrowthN/ABiofrontera Announcement DetailsQuarterQ1 2026Date5/14/2026TimeAfter Market ClosesConference Call DateThursday, May 14, 2026Conference Call Time11:00AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Biofrontera Earnings HeadlinesBiofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic KeratosisMay 13 at 9:00 AM | globenewswire.comBiofrontera (BFRI) Projected to Post Quarterly Earnings on ThursdayMay 13 at 4:17 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 14 at 1:00 AM | Profits Run (Ad)Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026May 8, 2026 | markets.businessinsider.comReviewing Biofrontera (NASDAQ:BFRI) & Vertex Pharmaceuticals (NASDAQ:VRTX)May 7, 2026 | americanbankingnews.comBiofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...March 20, 2026 | finance.yahoo.comSee More Biofrontera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email. Email Address About BiofronteraBiofrontera (NASDAQ:BFRI) AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue. The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis. Ameluz is used in combination with the BF-RhodoLED® lamp, a medical device designed to emit the precise wavelength of red light required to activate the gel. This integrated pharmaceutical–device approach underpins the company’s position in the PDT market. Founded in 1997 and headquartered in Leverkusen, Germany, Biofrontera maintains operations in multiple geographies, including a U.S. subsidiary established to support commercialization efforts in North America. Beyond its approved indications, the company is exploring additional dermatological uses for its photodynamic platform and is engaged in discussions with regulatory authorities and commercial partners to expand its presence in key markets such as Canada, Turkey and beyond. Biofrontera’s management team brings together expertise in dermatology, pharmaceutical development and medical device manufacturing. The company continues to invest in its pipeline, seeking to leverage its PDT technology for new indications and to forge strategic partnerships that will broaden access to its therapies worldwide.View Biofrontera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings Miss Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
